Fax: (615) 342-1745
Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma
A Minnie Pearl Cancer Research Network Phase II Trial†
Article first published online: 3 MAY 2004
Copyright © 2004 American Cancer Society
Volume 100, Issue 11, pages 2437–2441, 1 June 2004
How to Cite
Hainsworth, J. D., Carrell, D., Drengler, R. L., Scroggin, C. and Greco, F. A. (2004), Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma. Cancer, 100: 2437–2441. doi: 10.1002/cncr.20281
Participants in the Minnie Pearl Cancer Research Network include the following institutions: Tennessee Oncology (Nashville, TN); South Texas Oncology and Hematology (San Antonio, TX); Northeast Arkansas Clinic (Jonesboro, AR); Atlanta Cancer Care (Atlanta, GA); Northwest Georgia Oncology Centers (Marietta, GA); Consultants in Blood Disorders & Cancer (Louisville, KY); The Medical Oncology Group (Gulfport, MS); Upstate Carolina CCOP (Spartanburg, SC); Northeast Georgia Medical Center (Gainesville, GA); Phoebe Cancer Center (Albany, GA); Associates in Oncology and Hematology (Chattanooga, TN); Emerywood Internal Medicine & Oncology (High Point, NC); St. Vincent Hospital Cancer Center (Green Bay, WI); St. Louis Cancer Care (Chesterfield, MO); and Columbia Oncology (Columbia, TN).
- Issue published online: 18 MAY 2004
- Article first published online: 3 MAY 2004
- Manuscript Revised: 16 MAR 2004
- Manuscript Accepted: 16 MAR 2004
- Manuscript Received: 2 SEP 2003
- Eli Lilly
- Minnie Pearl Foundation
- small cell lung carcinoma
The goal of the current study was to evaluate the feasibility, toxicity, and efficacy of a novel combination of weekly docetaxel and gemcitabine for elderly patients and patients with poor performance status who had advanced-stage small cell lung carcinoma (SCLC).
Previously untreated patients with advanced-stage SCLC were eligible for the current clinical trial. In addition, patients were required to be age > 65 years or to have poor performance status (Eastern Cooperative Oncology Group 2). All patients received 800 mg/m2 gemcitabine and 30 mg/m2 docetaxel intravenously on Days 1, 8, and 15. Courses were repeated at 28-day intervals.
Forty patients were enrolled in the current multicenter, community-based trial. Nine patients (23%) had partial responses to treatment. The median survival for the entire group was 4 months. Fourteen percent of patients were alive at 1 year. Myelosuppression was mild to moderate, with no episodes of neutropenia and fever. Grade 3/4 fatigue (25%) was the only common nonhematologic toxicity.
Although relatively well tolerated, the weekly regimen of gemcitabine and docetaxel possessed only modest activity in this group of patients with unfavorable prognosis. The regimen offered no potential advantages over standard treatment approaches and is not recommended for further development. Cancer 2004. © 2004 American Cancer Society.